Skip to main content

Advertisement

SpringerLink
Log in

A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis

  • Scientific Paper (other)
  • Non-Vascular Interventions
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Background

Pulmonary metastasectomy has been widely adopted in the treatment of metastatic disease. In recent years image guided ablation has seen increased use in the treatment of thoracic malignancies. The objective of this study was to evaluate oncological outcomes following percutaneous ablation (PA) of pulmonary metastasis.

Methods

A comprehensive search of the PubMed, MEDLINE and EMBASE databases from January 2000 to August 2021 was performed to identify studies evaluating patient survival following ablation of lung metastasis. Pooled outcomes have been presented with a random effects model to assess primary outcomes of overall survival, progression free survival and 1-year local control. Secondary outcomes included procedural mortality, major complications, and the incidence of pneumothorax.

Results

A total of 24 studies were identified. The pooled median overall survival was 5.13 [95% confidence interval (CI): 4.37–6.84] years, and the 1-, 3-, 5-year progression free survival rates were 53%, 26% and 20% respectively. The 1-year local control rate was 91% (95%CI: 86–95%). Periprocedural mortality was rare (0%; 95%CI: 0–1%), as were major complications excluding pneumothorax (1%; 95%CI: 1–2%). Pneumothorax developed in 44% of ablation sessions, although only half of these required chest tube placement. Most patients were able to be discharged day one post-procedurally.

Conclusion

PA demonstrates high overall, progression free and local tumour survival in patients with lung metastasis. Complications and mortality are also rare. Consideration of its use should be made in a tumour board meeting in conjunction with surgical and radiotherapy perspectives for targeted local control of metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hess KR, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.

    Article  PubMed  Google Scholar 

  2. Pastorino U, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.

    Article  CAS  PubMed  Google Scholar 

  3. de Baere T, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240(2):587–96.

    Article  PubMed  Google Scholar 

  4. Dupuy DE, et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174(1):57–9.

    Article  CAS  PubMed  Google Scholar 

  5. Paez-Carpio A, et al. Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art. Insights Imaging. 2021;12(1):57.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Nguyen CL, et al. Radiofrequency ablation of primary lung cancer: results from an ablate and resect pilot study. Chest. 2005;128(5):3507–11.

    Article  PubMed  Google Scholar 

  7. Lencioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9(7):621–8.

    Article  PubMed  Google Scholar 

  8. Jiang B, et al. Efficacy and safety of thermal ablation of lung malignancies: a Network meta-analysis. Ann Thorac Med. 2018;13(4):243–50.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.

    Article  PubMed  Google Scholar 

  10. Trotti A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.

    Article  PubMed  Google Scholar 

  11. Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33(15):2521–37.

    Article  PubMed  Google Scholar 

  12. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–60.

    Article  PubMed  Google Scholar 

  13. Higgins JP, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bin Traiki TA, et al. Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(10):1939–48.

    Article  CAS  PubMed  Google Scholar 

  16. Bonichon F, et al. Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network. Endocrine. 2021;72(3):798–808.

    Article  CAS  PubMed  Google Scholar 

  17. Callstrom MR, et al. Multicenter study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE). J Thorac Oncol. 2020;15(7):1200–9.

    Article  PubMed  PubMed Central  Google Scholar 

  18. de Baère T, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987–91.

    Article  PubMed  PubMed Central  Google Scholar 

  19. de Baere T, et al. The ECLIPSE study: efficacy of cryoablation on metastatic lung tumors with a 5-year follow-up. J Thorac Oncol. 2021;16(11):1840–9.

    Article  PubMed  CAS  Google Scholar 

  20. Gonnet A, et al. Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience. BMC Cancer. 2019;19(1):1182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hasegawa T, et al. Three-year survival rate after radiofrequency ablation for surgically resectable colorectal lung metastases: a prospective multicenter study. Radiology. 2020;294(3):686–95.

    Article  PubMed  Google Scholar 

  22. Hiraki T, et al. Percutaneous radiofrequency ablation for pulmonary metastases from hepatocellular carcinoma: results of a multicenter study in Japan. J Vasc Interv Radiol. 2011;22(6):741–8.

    Article  PubMed  Google Scholar 

  23. Kawamura M, et al. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. J Thorac Cardiovasc Surg. 2006;131(5):1007–13.

    Article  PubMed  Google Scholar 

  24. Koelblinger C, Strauss S, Gillams A. Outcome after radiofrequency ablation of sarcoma lung metastases. Cardiovasc Intervent Radiol. 2014;37(1):147–53.

    Article  PubMed  Google Scholar 

  25. Leppelmann KS, et al. Outcomes following percutaneous microwave and cryoablation of lung metastases from adenoid cystic carcinoma of the head and neck: a bi-institutional retrospective cohort study. Ann Surg Oncol. 2021;28(11):5829–39.

    Article  PubMed  Google Scholar 

  26. Matsui Y, et al. Long-term survival following percutaneous radiofrequency ablation of colorectal lung metastases. J Vasc Interv Radiol. 2015;26(3):303–10.

    Article  PubMed  Google Scholar 

  27. Nakamura T, et al. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas [corrected]. Cancer. 2009;115(16):3774–81.

    Article  PubMed  Google Scholar 

  28. Omae K, et al. Long-term survival after radiofrequency ablation of lung oligometastases from five types of primary lesions: a retrospective evaluation. J Vasc Interv Radiol. 2016;27(9):1362–70.

    Article  PubMed  Google Scholar 

  29. Pennathur A, et al. Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg. 2009;88(5):1601–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sato T, et al. Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients. Jpn J Radiol. 2017;35(2):61–7.

    Article  PubMed  Google Scholar 

  31. Simon CJ, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243(1):268–75.

    Article  PubMed  Google Scholar 

  32. Soga N, et al. Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. BJU Int. 2009;104(6):790–4.

    Article  PubMed  Google Scholar 

  33. Tselikas L, et al. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. Diagn Interv Imaging. 2021;102(1):19–26.

    Article  CAS  PubMed  Google Scholar 

  34. von Meyenfeldt EM, et al. Local progression after radiofrequency ablation for pulmonary metastases. Cancer. 2011;117(16):3781–7.

    Article  Google Scholar 

  35. Yamakado K, et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol. 2007;18(3):393–8.

    Article  PubMed  Google Scholar 

  36. Yamakado K, et al. Long-term results of radiofrequency ablation in colorectal lung metastases: single center experience. Oncol Rep. 2009;22(4):885–91.

    Article  PubMed  Google Scholar 

  37. Yan TD, et al. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14(5):1718–26.

    Article  PubMed  Google Scholar 

  38. Zhong J, et al. Long-term outcomes in percutaneous radiofrequency ablation for histologically proven colorectal lung metastasis. Cardiovasc Intervent Radiol. 2020;43(12):1900–7.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.

    Article  CAS  PubMed  Google Scholar 

  40. Leung KM, Elashoff RM, Afifi AA. Censoring issues in survival analysis. Annu Rev Public Health. 1997;18:83–104.

    Article  CAS  PubMed  Google Scholar 

  41. Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017;15(1):133.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Sun YD, et al. Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: a systematic review and meta-analysis. Thorac Cancer. 2019;10(3):543–50.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Dziedzic R, et al. Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg. 2017;52(2):363–9.

    Article  PubMed  Google Scholar 

  44. Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S.

    Article  CAS  PubMed  Google Scholar 

  45. Gossling GCL, et al. Outcomes and prognostic factors of patients with metastatic colorectal cancer who underwent pulmonary metastasectomy with curative intent: a Brazilian experience. Oncologist. 2021;26(9):e1581–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hornbech K, Ravn J, Steinbruchel DA. Outcome after pulmonary metastasectomy: analysis of 5 years consecutive surgical resections 2002–2006. J Thorac Oncol. 2011;6(10):1733–40.

    Article  PubMed  Google Scholar 

  47. Cao C, et al. A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. J Thorac Dis. 2019;11(12):5187–98.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Cumpston M, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.

    PubMed  Google Scholar 

  49. Hess LM, et al. Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. J Cancer. 2019;10(16):3717–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Lodeweges JE, et al. Long-term outcome of surgery or stereotactic radiotherapy for lung oligometastases. J Thorac Oncol. 2017;12(9):1442–5.

    Article  PubMed  Google Scholar 

  51. Cheung FP, Alam NZ, Wright GM. The past, present and future of pulmonary metastasectomy: a review article. Ann Thorac Cardiovasc Surg. 2019;25(3):129–41.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Liu J, et al. The application of computed tomography-guided percutaneous coaxial biopsy combined with microwave ablation for pulmonary tumors. J Cancer Res Ther. 2019;15(4):760–5.

    Article  PubMed  Google Scholar 

  53. Tselikas L, et al. Diagnostic yield of a biopsy performed immediately after lung radiofrequency ablation. Eur Radiol. 2017;27(3):1211–7.

    Article  PubMed  Google Scholar 

  54. Milosevic M, et al. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients—control survival is much better than previously assumed. Colorectal Dis. 2020;22(10):1314–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Palma DA, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8.

    Article  PubMed  Google Scholar 

  56. Ruers T, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djx015.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: “when is enough, enough?” JAMA. 2008;299(22):2667–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was not supported by any funding.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Western Hospital, Footscray, Melbourne, VIC, 3011, Australia

    Minhtuan Nguyenhuy, Stephen Barnett & Simon Knight

  2. Department of Surgery, Peninsula Health, Frankston, VIC, 3199, Australia

    Yifan Xu

  3. Department of Interventional Radiology, Monash Health, Clayton, VIC, 3168, Australia

    Julian Maingard & Simon Knight

  4. Department of Thoracic Surgery, Austin Health, Heidelberg, VIC, 3084, Australia

    Stephen Barnett

  5. Interventional Radiology Service, Northern Health Radiology, Epping, VIC, 3076, Australia

    Hong Kuan Kok

  6. Department of Interventional Radiology, Austin Health, Heidelberg, VIC, Australia

    Mark Brooks & Hamed Asadi

  7. Department of Vascular and Interventional Radiology, St Vincent’s Hospital, Fiztroy, VIC, 3065, Australia

    Ashu Jhamb

Authors
  1. Minhtuan Nguyenhuy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yifan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julian Maingard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen Barnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong Kuan Kok
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ashu Jhamb
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hamed Asadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Simon Knight
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minhtuan Nguyenhuy.

Ethics declarations

Conflict of interest

The author(s) declare(s) that there is no conflict of interest.

Ethical Approval

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nguyenhuy, M., Xu, Y., Maingard, J. et al. A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis. Cardiovasc Intervent Radiol 45, 1102–1113 (2022). https://doi.org/10.1007/s00270-022-03116-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-022-03116-z

Keywords

Search

Navigation